Patient reported outcomes in the FDA approved drugs for systemic rheumatic diseases (2013-2024)
{{output}}
Background: Patient-reported outcomes (PROs) in systemic rheumatic diseases (SRDs) are in the forefront of clinical research. However, a comprehensive evaluation of PROs in pivotal trials supporting SRD drug approval is lacking. ... ...